Createrna Science

Executive Summary

Createrna Science is a private, preclinical-stage Chinese biotechnology company founded in 2019 and headquartered in Shanghai. The company is pioneering next-generation RNA therapeutics and novel delivery platforms, aiming to develop precise, potent, and durable treatments for diseases with high unmet medical need. With a lean team of 1–50 employees, Createrna is focused on building a pipeline of RNA-based drugs, leveraging its proprietary technology to address limitations in stability, targeting, and immunogenicity. Operated in stealth-like mode, the company represents early-stage innovation in the rapidly evolving RNA therapeutics space, capitalizing on China's growing biotech ecosystem. Despite its promising focus, Createrna Science faces typical early-stage risks including limited funding visibility, preclinical uncertainty, and regulatory pathways in China. No pipeline details or public financing rounds have been disclosed, making it difficult to gauge progress. However, the company's strategic alignment with high-growth RNA modalities—such as mRNA, siRNA, or circular RNA—and its location in Shanghai's biotech hub position it for potential value creation if it can advance its lead candidates to clinical trials. The company's success hinges on securing partnerships or funding to move toward IND-enabling studies.

Upcoming Catalysts (preview)

• Q4 2026Lead Program IND Filing30% success
• Q3 2026Series A / Seed Extension Financing40% success
• TBDResearch Collaboration or Licensing Deal20% success